MedPath

Role of Sleep Reactivity in Shift Work Disorder

Not Applicable
Recruiting
Conditions
Shift-work Disorder
Interventions
Behavioral: Active phototherapy
Behavioral: Control phototherapy
Behavioral: Cognitive Behavioral Therapy (CBT)
Behavioral: Sleep education control
Registration Number
NCT05424406
Lead Sponsor
Henry Ford Health System
Brief Summary

The purpose of this project is to test sleep reactivity as an independent cause of Shift Work Disorder (SWD). The primary hypothesis is that those with high sleep reactivity will show persistent SWD symptoms after experimental reduction of circadian misalignment, which will then be mitigated with CBT.

Detailed Description

The first aim of this study is to establish sleep reactivity as a predictor of insomnia in SWD independent from circadian misalignment. The second aim of this study is to establish sleep reactivity as a predictor of sleepiness in SWD independent from circadian misalignment. The third aim of this study is to probe sleep reactivity as a cause of insomnia in SWD. The fourth aim of this study is to probe sleep reactivity as a cause of sleepiness in SWD.

Participants with Shift Work Disorder (SWD, N=150) with high and low sleep reactivity will be enrolled. This study will use a two-step mechanistic randomized controlled trial design stratified by high and low sleep reactivity to examine the independent effect of sleep reactivity in SWD after experimental reduction of circadian misalignment. The first step will experimentally reduce circadian misalignment compared to a control. Those who achieve reduced circadian misalignment (melatonin onset at or later than 4am, i.e., compromised phase position) and remain symptomatic will continue to the second step where sleep reactivity will be probed with CBT compared to a sleep education control.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Participants must be working a fixed nightshift schedule, operationalized as: a) working at least three night shifts a week, b) shifts must begin between 18:00 and 02:00, and last between 8 to 12 hours, and c) must also plan to maintain the nightshift schedule for the duration of the study
  • Participants must have Shift Work Disorder, which will be diagnosed based on ICSD-3 criteria
  • Participants must show circadian misalignment, operationalized as a baseline melatonin onset between 18:00 and 01:00.
  • Participants must be at least 18 years old
Exclusion Criteria
  • Insomnia disorder or excessive sleepiness predating the onset of shift work
  • Termination of nightshift schedule
  • Presence of other sleep disorders (e.g. obstructive sleep apnea, narcolepsy) determined by standard clinical polysomnography
  • Diagnosis of bipolar disorder
  • History of neurological disorders determined by self-report and medical history
  • Pregnancy
  • Alcohol use disorder
  • Illicit drug use via self-report and urine drug screen if reasonable suspicion to test

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Active light conditionActive phototherapyTimed bright light exposure will be delivered in a controlled laboratory setting (10,000 lux) designed to delay the DLMO to 4 am or later. This would shift the circadian nadir (e.g., the period of maximal sleepiness) into the typical daytime sleep period after the nightshift (i.e., circadian nadir at \~10am). Bright light will be delivered in a controlled lab environment using a full spectrum light-box with UV filter (Sunbox Sunray II) to achieve a robust reduction of circadian misalignment. The light schedule will be tailored to each individual nightshift worker, determined by: 1) their baseline circadian phase, and 2) the human phase response curve adjusted to the individual's baseline circadian phase.
Control light conditionControl phototherapyShift workers randomized to the control condition will receive less intense light that still has a perceptible alerting effect (100 photopic lux). However, light will occur during a portion of the phase response curve with minimal phase shifts.
Cognitive Behavioral Therapy (CBT) conditionCognitive Behavioral Therapy (CBT)The CBT condition will probe sleep reactivity using validated CBT strategies over 6 sessions in accordance with the two-factor theory of emotion. Behavioral strategies will be used to reduce physiological arousal (e.g., relaxation training, breathing) and to strengthen behavioral cues for sleep (e.g., sleep hygiene and sleep scheduling). Sleep times will be scheduled to align with the reduced circadian misalignment (compromised phase position, i.e., maintaining a slightly delayed sleep period on offwork days). Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
Sleep education control conditionSleep education controlThis condition will use an established sleep education control protocol modified for nightshift workers based on the "Plain Language about Shiftwork" published by the National Institute for Occupational Safety and Health (NIOSH). Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
Primary Outcome Measures
NameTimeMethod
Dim light melatonin onsetWithin two days of treatment for a duration of 24 hours

Melatonin values will be measured in saliva samples, collected in dim light conditions in a laboratory, to determine circadian phase.

Sleep reactivityWithin two weeks of treatment

Sleep reactivity will be measured using the validated Ford Insomnia Response to Stress Test (FIRST). Based on psychometric testing of the FIRST, a cutoff score of 16 will distinguish high and low sleep reactivity.

Secondary Outcome Measures
NameTimeMethod
InsomniaWithin one week of post-treatment

Insomnia will be measured with the Insomnia Severity Scale (0 to 28; higher scores correspond to worse severity)

SleepinessWithin one week of post-treamtnet

Sleepiness will be measured with the Epworth Sleepiness Scale (0 to 24; a score of 10 or greater indicates excessive sleepiness).

Trial Locations

Locations (1)

Henry Ford Columbus Medical Center

🇺🇸

Novi, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath